Developmental Funds have had a high scientific impact during the project period. Developmental Funds were used to support the external recruitment of nine New Investigators who have brought scientific expertise in high priority areas, the development of a new Circulating Tumor Cell Shared Resource that provides unique technology and exceptional scientific expertise in this burgeoning area, and the funding of a pilot project that has contributed to our growing Adolescent and Young Adult Program. These accomplishments were funded by a total of $545,000 in Developmental Funds during the four year project period (approximately $130,000 per year): $425,000 for New Investigators, $50,000 for Pilot Projects and $70,000 for Developing Shared Resources. In this application, we request a budget of $450,000 per year for Developmental Funds. Of this amount, $200,000 will be allocated for the recruitment of New Investigators in high priority research areas, $200,000 for the development of a new Bioinformatics Shared Resource, and $50,000 for novel pilot projects with the potential to secure external funding. Developmental Funds will be critical to growing our research base and increasing collaborative research in targeted areas. The focus of annual pilot project program, priorities for New Investigators support, and plans for Shared Resources will continue to be developed with input from Senior and Program Leaders and guided by advice from our External Advisory Board.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-45S7
Application #
10303164
Study Section
Subcommittee H - Clinical Groups (NCI)
Program Officer
He, Min
Project Start
1996-12-01
Project End
2021-11-30
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110
Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640

Showing the most recent 10 out of 842 publications